Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults


Autoria(s): Bertolini, Daniela Vinhas; Costa, Luciana Scarlazzari; van der Heijden, Inneke Marie; Sato, Helena Keiko; de Sousa Marques, Heloisa Helena
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

Children and adolescents infected with HIV typically have a lower response to immunization than do those in the general population. In most developed countries, meningococcal serogroup C conjugate vaccine is one of the recommended vaccines for such individuals. However, there have been no studies evaluating the antibody response to this vaccine in HIV-infected children, adolescents or young adults. In this study, we evaluated that response using serum bactericidal antibody (SBA) and enzyme-linked immunosorbent assay, comparing HIV-infected with non-HIV-infected patients, as well as analysing the occurrence of side effects. In non-responders, we assessed the antibody response to revaccination. This clinical trial involved 92 patients between 10 and 20 years of age: 43 HIV-infected patients (HIV+ group) and 49 non-HIV-infected patients (HIV- group). After one dose of the vaccine, 72.1% of the HIV+ group patients and 100% of the HIV- group patients were considered protected. Of the HIV+ group patients who received a second dose of the vaccine, only 40% acquired protection. Overall, 81.4% of the HIV+ group patients acquired protection (after one or two doses of the vaccine). Side effects occurred in 16.3% and 44% of the HIV+ group and HIV- group patients, respectively. Therefore, the meningococcal serogroup C conjugate vaccine proved to be safe and effective for use in HIV-infected children, adolescents, and young adults, although their antibody response was weaker than that shown by non-HIV-infected patients. This indicates the need to discuss changes to the immunization schedule for children, adolescents, and young adults infected with HIV, in order to ensure more effective protection against meningococcal disease. (c) 2012 Elsevier Ltd. All rights reserved.

Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for Scientific and Technological Development) [478687/2008-7]

Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Council for Scientific and Technological Development)

Identificador

VACCINE, OXFORD, v. 30, n. 37, supl. 2, Part 3, pp. 5482-5486, AUG 10, 2012

0264-410X

http://www.producao.usp.br/handle/BDPI/37701

10.1016/j.vaccine.2012.06.069

http://dx.doi.org/10.1016/j.vaccine.2012.06.069

Idioma(s)

eng

Publicador

ELSEVIER SCI LTD

OXFORD

Relação

VACCINE

Direitos

closedAccess

Copyright ELSEVIER SCI LTD

Palavras-Chave #HIV #MENINGOCOCCAL VACCINE #IMMUNIZATION #CHILDREN #ADOLESCENTS #HUMAN-IMMUNODEFICIENCY-VIRUS #IMMUNE-RESPONSE #UNITED-KINGDOM #GROUP-A #PROTECTION #EFFICACY #ANTIBODY #DISEASE #INDIVIDUALS #SAFETY #IMMUNOLOGY #MEDICINE, RESEARCH & EXPERIMENTAL
Tipo

article

original article

publishedVersion